Skip to main content

Advertisement

SpringerLink
Log in

First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Peripheral T cell lymphomas (PTLs) have a globally poor prognosis. The CHOP regimen shows insufficient efficacy; first-line consolidation with autologous stem cell transplantation (auto-SCT) is a promising strategy but has never been confirmed by randomized data. We analyzed retrospectively 906 patients diagnosed with PTL between 1999 and 2015. Chemotherapy was given to 862 patients, and 412 of them were < 60 years. In this subset, we compared induction with CHOP (n = 113) vs. CHOEP (n = 68) and tested auto-SCT (n = 79) vs. no SCT (n = 73) in the intent-to-treat analysis. The median age of the whole cohort at diagnosis was 60 years (range; 18–91); the median follow-up was 4.3 years (range; 0.1–17.8). A shorter overall survival (OS) was associated with the male gender, age ≥ 60 years, stage III/IV, performance status ≥ 2, bulky tumor ≥ 10 cm, and elevated LDH. CHOEP induction showed a better 5-year PFS (25.0% vs. 32.9%; p.001), and 5-year OS (65.6% vs. 47.6%; p.008) than CHOP. Auto-SCT compared to no SCT brought a 5-year OS of 49.2% vs. 59.5% (p.187). Auto-SCT did not influence the OS in low-risk or low-intermediate risk PTLs. The high-intermediate and high-risk IPIs displayed a worse 5-year OS in auto-SCT arm (17.7% vs.46.2%; p.049); however, 73.9% of the patients never received planned auto-SCT. Our population-based analysis showed the superiority of CHOEP over CHOP in first-line treatment. We confirm the 5-year OS of around 50% in PTLs undergoing auto-SCT. However, the intended auto-SCT could not be given in 73.9% of the high-risk PTLs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Foss FM, Zinzani PL, Vose JM et al (2011) Peripheral T cell lymphoma. Blood 117(25):6756–6767

    Article  CAS  PubMed  Google Scholar 

  2. Adams SV, Newcomb PA, Shustov AR (2016) Racial Patterns of Peripheral T cell Lymphoma Incidence and Survival in the United States. J Clin Oncol 34(9):963–971

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Ellin F, Landström J, Jerkeman M, Relander T (2014) Real-world data on prognostic factors and treatment in peripheral T cell lymphomas: a study from the Swedish Lymphoma Registry. Blood 124(10):150–1577

    Article  CAS  Google Scholar 

  4. Schmitz N, Trümper L, Ziepert M et al (2010) Treatment and prognosis of mature T cell and NK-cell lymphoma: an analysis of patients with T cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 116(18):3418–3425

    Article  CAS  PubMed  Google Scholar 

  5. Weisenburger DD, Savage KJ, Harris NL et al (2011) Peripheral T cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T cell Lymphoma Project. Blood 117:3402–3408

    Article  CAS  PubMed  Google Scholar 

  6. Federico M, Rudiger T, Bellei M et al (2013) Clinicopathologic characteristics of angioimmunoblastic T cell lymphoma: analysis of the International Peripheral T cell lymphoma Project. J Clin Oncol 31(2):240–246

    Article  CAS  PubMed  Google Scholar 

  7. Sibon D, Fournier M, Briere J et al (2012) Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte Trials. J Clin Oncol 30:3939–3946

    Article  PubMed  Google Scholar 

  8. Tse E, Kwong YL (2016) Diagnosis and management of extranodal NK/T cell lymphoma nasal type. Expert Rev Hematol 9:861–871

    Article  CAS  PubMed  Google Scholar 

  9. Petrich AM, Helenowski IB, Bryan LJ et al (2015) Factors predicting survival in peripheral T cell lymphoma in the USA: a population-based analysis of 8802 patients in the modern era. Br J Hematol 168:708–718

    Article  Google Scholar 

  10. Vazquez A, Khan MN, Blake DM et al (2014) Extranodal natural killer/T cell lymphoma: a population based comparison of sinonasal and extranasal disease. Laryngoscope 124(4):888–895

    Article  PubMed  Google Scholar 

  11. Wang YQ, Yang Y, Zhuo HY et al (2015) Trial of LVDP regimen (L-asparaginase, etoposide, dexamethasone, and cisplatin, followed by radiotherapy) as first-line treatment for newly diagnosed, stage III/IV extranodal natural killer/T cell lymphoma. Med Oncol 32:9

    Article  CAS  Google Scholar 

  12. D’Amore F, Relander T, Lauritzsen GF et al (2012) Up-front autologous stem-cell transplantation in peripheral T cell lymphoma: NLG-T-01. J Clin Oncol 30:3093–3099

    Article  CAS  PubMed  Google Scholar 

  13. D’Amore F, Relander T, Lauritzsen G et al (2015) Ten years median follow-up of the Nordic NLG-T-01 trial on CHOEP and upfront autologous transplantation in peripheral T cell lymphomas. Hematol Oncol 33(Suppl 1):139 (Abstract No 074)

    Google Scholar 

  14. Swerdlow SH, Campo E, Harris NL et al (2008) WHO Classification of tumors of hematopoietic and lymphoid tissues, 4th edn. International Agency for Research on cancer (IARC), Lyon

    Google Scholar 

  15. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M (1971) Report of the Committee on no Hodgkin’s Disease Staging Classification. Cancer Res 31:1860–1861

    CAS  PubMed  Google Scholar 

  16. Sykorova A, Belada D, Smolej L et al (2010) Staging of non-Hodgkin’s lymphoma –recommendations of the Czech Lymphoma Study Group. Klin Onkol 23:146–154

    CAS  PubMed  Google Scholar 

  17. Cheson BD, Horning SJ, Coiffier B et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17(4):1244

    Article  CAS  PubMed  Google Scholar 

  18. Cheson BD, Pfistner B, Juweid ME et al (2007) International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579–586

    Article  PubMed  Google Scholar 

  19. Shipp MA (1994) Prognostic factors in aggressive non-Hodgkin’s lymphoma: who has “high-risk” disease? Blood 83(5):1165–1173

    CAS  PubMed  Google Scholar 

  20. Gallamini A, Stelitano C, Calvi R et al (2004) Intergruppo Italiano Linfomi. Peripheral T cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 103(7):2474–2479

    Article  CAS  PubMed  Google Scholar 

  21. Chiu BC, Hou N (2015) Epidemiology and etiology of non-hodgkin lymphoma. Cancer Treat Res 165:1–25

    Article  PubMed  Google Scholar 

  22. Haverkos BM, Pan Z, Gru AA et al (2016) Extranodal NK/T cell lymphoma, nasal type (ENKTL-NT): An update on epidemiology, clinical presentation, and natural history in North American and European cases. Curr Hematol Malig Rep 11(6):514–527

    Article  PubMed  PubMed Central  Google Scholar 

  23. Pedersen MB, Hamilton-Dutoit SJ, Bendix K et al (2015) Evaluation of clinical trial eligibility and prognostic indices in a population-based cohort of systemic peripheral T cell lymphomas from the Danish Lymphoma Registry. Hematol Oncol 33:120–128

    Article  CAS  PubMed  Google Scholar 

  24. Laurent C, Baron M, Amara N et al (2017) Impact of expert pathologic review of lymphoma diagnosis: study of patients from the French Lymphopath Network. JCO 35(18):2008–2017

    Article  Google Scholar 

  25. Bellei M, Sabattini E, Pesce EA et al (2017) Pitfalls and major issues in the histologic diagnosis of peripheral T cell lymphomas: results of the central review of 573 cases from the T cell Project, an international, cooperative study. Hematol Oncol 35(4):630–636

    Article  PubMed  Google Scholar 

  26. Iqbal J, Wright G, Wang C et al (2014) Gene expression signatures delineate and prognostic subgroups in peripheral T cell lymphoma. Blood 123(19):2915–2923

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Siaghani PJ, Song JY (2018) Updates of peripheral T cell lymphomas based on the 2017 WHO classification. Curr Hematol Malig Rep 13:25–36

    Article  PubMed  Google Scholar 

  28. Ambramson JS, Feldman T, Kroll-Desrosiers AR et al (2014) Peripheral T cell lymphoma in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol 25(11):2211–2217

    Article  Google Scholar 

  29. Federico M, Bellei M, Marcheselli L et al (2018) Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network. Br J Hematol 181:760–769

    Article  CAS  Google Scholar 

  30. Cederleuf H, Bjerregard Pedersen M, Jerkeman M et al (2017) The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: a Nordic Lymphoma Group study. Br J Hematol 178(5):739–746

    Article  CAS  Google Scholar 

  31. Kharfan-Dabaja MA, Kumar A, Ayala E et al (2017) Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T cell and NK/T cell lymphomas: an International Collaborative Effort on Behalf of the Guidelines Comitee of the American Society for Blood and Marrow Transplantation; 23:1826–1838

  32. Wilhelm M, Smetak M, Reimer P et al (2016) First-line therapy of peripheral T cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation. Blood Cancer J 6:e 452

    Article  CAS  Google Scholar 

  33. Rohlfing S, Dietrich S, Witzens-Harig M et al (2018) The impact of stem cell transplantation on the natural course of peripheral T cell lymphoma: a real-world experience. Ann Hematol 97(7):1241–1250

    Article  PubMed  Google Scholar 

  34. Park SI, Horwitz SM, Foss FM et al (2019) The role of autologous stem cell transplantation in patients with nodal peripheral T cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. Cancer. https://doi.org/10.1002/cncr.31861

  35. Mercadal S, Briones J, Xicoy B et al (2008) Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T cell lymphoma. Ann Oncol 19:958–963

    Article  CAS  PubMed  Google Scholar 

  36. Corradini P, Tarella C, Zallio F et al (2006) Long-term follow-up of patients with peripheral T cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 20:1533–1538

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This work was supported by research grants from the Ministry of Education and Youth of the Czech Republic AZV CR 16-31092A. On behalf of CLSG.

Author information

Authors and Affiliations

  1. Department of Internal Medicine–Hematology and Oncology, Masaryk University and University Hospital Brno, Jihlavska 20, 62500, Brno, Czech Republic

    Andrea Janikova, Natasa Kopalova & Jiri Mayer

  2. Institute of Biostatistics and Analyses, Faculty of Medicine Masaryk University, Brno, Czech Republic

    Renata Chloupkova & Zbynek Bortlicek

  3. Department of Pathology and Molecular Medicine, 2nd Faculty of Medicine, Charles University and Faculty Hospital in Motol, Prague, Czech Republic

    Vit Campr

  4. 1st Department of Medicine, First Medical Faculty, Charles University and General University Hospital, Prague, Czech Republic

    Pavel Klener, Jitka Hamouzova, Robert Pytlik & Marek Trneny

  5. 4th Department of Internal Medicine–Hematology, Charles University Hospital and Faculty of Medicine, Hradec Králové, Czech Republic

    David Belada

  6. Department of Hematology, University Hospital Olomouc, Olomouc, Czech Republic

    Vit Prochazka

  7. Department of Oncology, Hospital Ceske Budejovice, Ceske Budejovice, Czech Republic

    Jan Pirnos

  8. Department of Clinical Hematology, Teaching Hospital Ostrava, Ostrava, Czech Republic

    Juraj Duras

  9. Internal Clinic of Haematology, University Hospital Kralovske Vinohrady, Prague, Czech Republic

    Heidi Mocikova

  10. 3rd Faculty of Medicine, Charles University in Prague, Prague, Czech Republic

    Heidi Mocikova

Authors
  1. Andrea Janikova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Renata Chloupkova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vit Campr
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pavel Klener
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jitka Hamouzova
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. David Belada
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Vit Prochazka
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Robert Pytlik
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jan Pirnos
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Juraj Duras
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Heidi Mocikova
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Zbynek Bortlicek
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Natasa Kopalova
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Jiri Mayer
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Marek Trneny
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrea Janikova.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in the study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Janikova, A., Chloupkova, R., Campr, V. et al. First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients. Ann Hematol 98, 1961–1972 (2019). https://doi.org/10.1007/s00277-019-03694-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-019-03694-y

Keywords

Search

Navigation